Capricor Therapeutics(US:CAPR) Globenewswire·2025-09-09 23:57Core Viewpoint - Rosen Law Firm is reminding investors who purchased Capricor Therapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on September 15, 2025 [1] Group 1: Class Action Details - Investors who purchased Capricor securities between October 9, 2024, and July 10, 2025, may be entitled to compensation through a contingency fee arrangement [2] - A class action lawsuit has been filed, and interested parties must move the Court to serve as lead plaintiff by September 15, 2025 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] Group 3: Case Specifics - The lawsuit alleges that Capricor provided misleading information regarding its lead drug candidate, deramiocel, while concealing adverse facts about its safety and efficacy data from a Phase 2 trial [5] - This misleading information allegedly led to shareholders purchasing securities at inflated prices, resulting in damages when the truth was revealed [5]